SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The $ROSIE project centers around a unique, AI-powered memecoin inspired by "Rosie the Robot," a beloved character known for her role as a caring, motherly robot in popular culture. The purpose of $ROSIE is twofold: entertainment through an interactive AI feature and social impact via charitable donations.  Users can interact with an AI version of Rosie on the project’s website, where they can ask questions and engage in conversations. The utility of $ROSIE goes beyond typical memecoins by enabling users to donate tokens, which will be directed towards charitable causes supporting mothers. Through this initiative, the project combines the viral appeal of meme tokens with meaningful contributions to social causes, while leveraging AI technology to create a novel user experience.

Rosie the Robot

ROSIE CRYPTO is gaining attention, particularly regarding its integration with Phantom Wallet. The community highlights the token's 'early moon' potential and strong momentum, suggesting a possible breakout. Bullish sentiment is building, with many emphasizing it as an opportune entry point.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending due to an FDA investigation into allergic reactions linked to specific lots of its and Grifols' immune globulin products, raising concerns about potential voluntary recalls and revenue impact. The community is discussing the extent of the issue, comparing it to a previous recall, and speculating on possible short-selling manipulation. Despite the concerns, some investors express confidence in the company's fundamentals and long-term growth potential, viewing the dip as a buying opportunity.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending due to renewed interest in its low float and potential for a short squeeze, with some traders drawing comparisons to other high-flying stocks. Community chatter highlights the company's potential crypto treasury and anticipation for news catalysts. Some are wary of the stock's history of volatility and advising caution.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community discusses its recent price movements and potential catalysts, including the ongoing government shutdown and anticipation of XRP ETFs.  Community members are debating entry points, long-term potential, and whether XRP can break through resistance levels.  Broader discussions include Ripple's partnerships and the potential impact of regulatory clarity on the crypto's future.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals ($SNDX) is trending due to an upcoming FDA decision on their drug Revuforj for a specific type of leukemia, with the community debating the likelihood of approval and its potential impact. Some traders point to the drug's existing approval for a related condition and analysts' price targets while others cite concerns about side effects and market manipulation. Discussions also mention potential competition and buyout scenarios.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending due to recent listing news and a surge in interest surrounding its AI agent ecosystem. Community members are actively discussing its potential, the utility of its agents, and possible price targets. The broader context includes the growing excitement around AI-related crypto projects and Base network tokens.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

Picard Medical (PMI) is trending due to recent stock volatility, leading the company to release a statement clarifying they are unaware of any undisclosed material changes. The community is actively discussing potential Monday catalysts, dilution concerns, and whether the stock presents a buying opportunity or a trap. Bullish sentiment revolves around the company's exclusive artificial heart technology and potential for a v-shape recovery.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is trending as its community rallies around the project, anticipating a significant breakout. The community, known as the Wolfpack, expresses strong conviction and emphasizes holding for long-term gains. Discussions highlight the project's potential and a belief that a substantial upward movement is on the horizon.

PAW Chain has launched the world’s first Layer 3-centric blockchain, enhancing scalability and inter-chain operability across networks. The roadmap features a decentralized exchange, merchant services, and a DAO, all optimized for high-volume, low-cost transactions. Leveraging smart contracts and EVM compatibility, PAW Chain is set to transform digital finance by providing secure, efficient solutions, allowing any project to go multi-chain, underscored by a community-driven governance model and rigorous security standards including regular security audits.

$PAW is trending amidst community excitement surrounding its multi-chain ecosystem and ongoing development, including news about new projects launching and validator updates. Community members express bullish sentiment, focusing on the project's potential for growth and interoperability. Discussions also highlight staking and upcoming partnerships.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community speculates on the impact of recent news and exchange listings. Community members are actively discussing price predictions and potential catalysts for growth, drawing comparisons to other meme coins. The listing and broader discussions around meme coins are driving interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Travere Therapeutics to Report Third Quarter 2025 Financial Results

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company...

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney...

NVS Reports Positive Late-Stage Data on Kidney Disease Drug 

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

What Makes Travere (TVTX) a New Strong Buy Stock

Travere (TVTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?

MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of...

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Travere Therapeutics (TVTX) on Wednesday said that the U.S. Food and Drug Administration informed the company that it has waived the need for an advisory committee meeting regarding its application for Filspari in treating focal segmental glomerulosclerosis (FSGS).The FDA is expected to decide on the company’s application by January 13, 2026. If approved, Filspari would be the first medication indicated for FSGS, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250910301976/en/Travere-Therapeutics-Provides-Update-on-FDA-Advisory-Committee-Meeting-for-FILSPARI-sparsentan-in-FSGS">said</a>. FSGS is a rare and serious kidney disorder driven by proteinuria or protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. The disease leads to progressive kidney function loss and kidney failure and is estimated to affect more than 40,000 patients in the U.S., according to Travere. &nbsp;Shares of the company soared 16% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.CEO Eric Dube said that the company is pleased with the progress of its new application for Filspari to date and is continuing preparation for a successful commercial launch in January, if approved.The company’s application is supported by data from mid-stage and late-stage studies where Filspari demonstrated rapid, superior, and sustained reductions in proteinuria when compared with the maximum labeled dose of the approved drug Irbesartan across adult and pediatric patients. The drug was also well-tolerated in the studies with a safety profile comparable to Irbesartan.Filspari is already approved by the FDA to slow kidney function decline in adults with IgA nephropathy, a chronic autoimmune kidney disease characterized by the abnormal accumulation of immunoglobulin A (IgA) antibodies in the kidneys' filtering units. The new application by the company seeks to expand its use to the treatment of FSGS as well.TVTX stock is up by 24% this year and by about 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-stock-rises-pre-market-after-company-announces-positive-efficacy-data-for-agitation-drug-in-study/chwk7aERdub">BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application

If approved, Filspari would be the first medication indicated for focal segmental glomerulosclerosis, a rare and serious kidney disorder driven by proteinuria, the company said. 

Equity

If approved, Filspari would be the first medication indicated for focal segmental glomerulosclerosis, a rare and serious kidney disorder driven by proteinuria, the company said. 


Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.30	--	--	N/A
Q2 '25	-$0.31	-$0.14	55.08%	BEAT
Q1 '25	-$0.57	-$0.47	17.11%	BEAT
Q4 '24	-$0.56	-$0.73	-29.89%	MISSED
Q3 '24	-$0.64	-$0.70	-9.39%	MISSED

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TVTX News

TVTXTravere Therapeutics Inc